Cited by 640Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNuclear Receptors and Signaling

The DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.

Epidemiology of parkinson’s disease

Open access

Tanner, Caroline M., Goldman, Samuel M.·1996·Neurologic Clinics

DOI 10.1016/s0733-8619(05)70259-0PMC PMC7173037

Open this paper in CoChat — free account

Abstract

The epidemiologic studies reviewed here have provided insights into the etiology of PD. Evidence increasingly suggests that, like many other chronic age-related diseases, PD is a multifactorial disorder, with both genes and environment contributing to risk. As the elderly population of the world grows, incidence and prevalence of PD will continue to increase, underscoring the importance of further delineating risk factors. The introduction of levodopa and other pharmacologic therapies over the last 2 decades has postponed disease morbidity and mortality, but morbidity and mortality still are increased markedly relative to unaffected individuals. The development of therapies that may slow disease progression makes early identification and treatment of PD particularly important. Investigations of early markers of PD, or markers of disease susceptibility, are critical areas for future research. These efforts all will be aided by careful collaboration between epidemiologists and laboratory scientists.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0733-8619(05)70259-0

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
An Essay on the Shaking Palsy
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Vitamin E Consumption and the Risk of Coronary Heart Disease in Men
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E. L., Colditz, G. A., & Willett, W. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282004 · Cited by 2,345
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463

Show all 240 references

Research works printed but not linked: 13

Breteler, 1995, Risk factors for Parkinson's disease: A population-based case-control study, Neurology, 45, A214
Campanella, 1990, Etiology of Parkinson's disease: Results of two case-control studies, Mov Disord, 5, 31
Davanipour, 1990, Residential histories in Parkinson's disease patients, Ann Neurol, 28, 295
Goetz, 1990, Motor vehicle accident and Parkinson's disease disability, Mov Disord, 5, 16
Kurth, 1995, Lack of association of CYP2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort, Neurology, 45, A429
Mjones, 1949, Paralysis agitans: A clinical and genetic study, Acta Psychiatry and Neurology, 54, 1
Rocca, 1990, Prevalence of Parkinson's disease and other parkinsonisms: A door-to-door survey in two Sicilian communities, Neurology, 40, 422
Tanner, 1989, Dietary antioxidant vitamins and the risk of developing Parkinson's disease, Neurology, 39, 181
Tanner, 1988, Vitamin use and Parkinson's disease, Ann Neurol, 233, 182
Treves, 1990, Case-control study, with use of temporal approach, for evaluation of risk factors for Parkinson's disease, Mov Disord, 5, 11
Uitti, 1991, Parkinsonism survival in the Levodopa era, Neurology, 41, 190
Vierregge, 1991, Parkinson's disease in twins, Neurology, 41, 255
Zimmerman, 1991, Parkinson's disease in monozygotic twins: A followup, Neurology, 41, 255

Sorted by citations

Items 101–200 of 640

Overexpression of Neutrophil Neuronal Nitric Oxide Synthase in Parkinson's Disease
Gatto, E. M., Galdo, N. A. R., Carreras, M. C., Cherñavsky, A. C., Rubio, A., Satz, M. L., & Poderoso, J. J. (2000) · Nitric Oxide · doi:10.1006/niox.2000.0288 · Cited by 117
Does This Patient Have Parkinson Disease?
Rao, G., Fisch, L., Srinivasan, S., D'Amico, F., Okada, T., Eaton, C., & Robbins, C. W. (2003) · JAMA · doi:10.1001/jama.289.3.347 · Cited by 115
Microglial activation in Parkinson’s disease using [18F]-FEPPA
Ghadery, C., Koshimori, Y., Coakeley, S., Harris, M., Rusjan, P., Kim, J., Houle, S., & Strafella, A. P. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0778-1 · Cited by 113
The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis
Enochs, W. S., Sarna, T., Zecca, L., Riley, P. A., & Swartz, H. M. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260963 · Cited by 116
“Proposed causes of the latter have included viral infection (Elizan and Casals, 1983; Mattock et al., 1988), arteriosclerosis (Issidorides, 1971; Bernheimer et al., 1973), heredity (Poirer et al., 1991; Tanner, 1992), environmental and endogenous toxins (Langston et al., 1987; Fahn, 1989; Goldsmith et al., 1990; Poiri…”
Background
The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis
McCann, S. J., Pond, S. M., James, K. M., & Couteur, D. G. L. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00179-2 · Cited by 115
Low frequency of pathogenic mutations in the ubiquitin carboxyterminal hydrolase gene in familial Parkinsonʼs disease
Lincoln, S., Vaughan, J. R., Wood, N., Baker, M. C., Adamson, J. L., Gwinn, K. A., Lynch, T., Hardy, J., & Farrer, M. J. (1999) · Neuroreport · doi:10.1097/00001756-199902050-00040 · Cited by 115
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
Kanwar, J. R., Sriramoju, & Kanwar (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30919 · Cited by 114
The Neurodegenerative Mitochondriopathies
Swerdlow, R. H. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1095 · Cited by 115
Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study
Pichler, I., Del Greco M., F., Gögele, M., Lill, C. M., Bertram, L., Do, C. B., Eriksson, N., Foroud, T., Myers, R. H., PD GWAS Consortium, et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001462 · Cited by 173
Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries
Henry, J., Smeyne, R. J., Jang, H., Miller, B. L., & Okun, M. S. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.06.012 · Cited by 110
Mitochondria: A Therapeutic Target for Parkinson’s Disease?
Luo, Y., Hoffer, A., Hoffer, B. J., & Qi, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920704 · Cited by 108
MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration
Xiong, R., Wang, Z., Zhao, Z., Li, H., Chen, W., Zhang, B., Wang, L., Wu, L., Li, W., Ding, J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.027 · Cited by 109
Parkinson’s Disease: Current and Future Challenges
Langston, J. W. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00098-0 · Cited by 109
Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: A cross-sectional study of patients with Parkinson’s disease and related neurological conditions
Saleem, T., Higginson, I. J., Chaudhuri, К. R., Martin, A., Burman, R., & Leigh, P. N. (2012) · Palliative Medicine · doi:10.1177/0269216312465783 · Cited by 106
Estrogen as Neuroprotectant of Nigrostriatal Dopaminergic System: Laboratory and Clinical Studies
Dluzen, D. E., & Horstink, M. W. I. M. (2003) · Endocrine · doi:10.1385/endo:21:1:67 · Cited by 106
DJ‐1 modulates the expression of Cu/Zn‐superoxide dismutase‐1 through the Erk1/2–Elk1 pathway in neuroprotection
Wang, Z., Liu, J., Chen, S., Wang, Y., Cao, L. H., Zhang, Y., Kang, W., Li, H., Gui, Y., Chen, S., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22514 · Cited by 105
The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk
Tanner, C. M., Goldman, S. M., Ross, G. W., & Grate, S. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.014 · Cited by 119
Self-citation
Brain molecular aging, promotion of neurological disease and modulation by Sirtuin5 longevity gene polymorphism
Glorioso, C. A., Oh, S., Douillard‐Guilloux, G., & Sibille, E. L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.09.016 · Cited by 105
Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease
Koutzoumis, D. N., Vergara, M., Pino, J. A., Buddendorff, J., Khoshbouei, H., Mandel, R. J., & Torres, G. E. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113159 · Cited by 103
Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage
Hauser, E. R., Li, Y., Takeuchi, S., Walters, R., Noureddine, M., Maready, M., Darden, T. A., Hulette, C., Martin, E. R., Hauser, E. R., et al. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg070 · Cited by 103
Extracellular Vesicles as Nanotherapeutics for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., L’Episcopo, F., Tirolo, C., Raciti, G., Pappalardo, F., Giachino, C., Caniglia, S., Serapide, M. F., et al. (2020) · Biomolecules · doi:10.3390/biom10091327 · Cited by 100
Management of Motor and Non-Motor Symptoms in Parkinson’s Disease
Sprenger, F., & Poewe, W. H. (2013) · CNS Drugs · doi:10.1007/s40263-013-0053-2 · Cited by 109
Genetics of iron regulation and the possible role of iron in Parkinson's disease
Rhodes, S. L., & Ritz, B. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.07.001 · Cited by 103
The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease
Zinger, A., Barcia, C., Herrero, M. T., & Guillemin, G. J. (2011) · Parkinson s Disease · doi:10.4061/2011/716859 · Cited by 99
Ultrasound targeted CNS gene delivery for Parkinson's disease treatment
Fan, C.-H., Lin, C.-Y., Liu, H.-L., & Yeh, C.-K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.004 · Cited by 97
Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population
Huerta, C., Castro, M. G., Coto, E., Estrada, M. B., Ribacoba, R., Guisasola, L. M., Salvador, C., Martínez, C., Lahoz, C. H., & Álvarez, V. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.04.016 · Cited by 96
Gender disparities in Parkinson’s disease
Shulman, L. M., & Bhat, V. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.407 · Cited by 96
Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance
Albuquerque, E. X., Pereira, E. F. R., Mike, Á., Eisenberg, H. M., Maelicke, A., & Alkondon, M. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00208-4 · Cited by 95
Levodopa: Effect on cell death and the natural history of Parkinson's disease
Olanow, C. W. (2014) · Movement Disorders · doi:10.1002/mds.26119 · Cited by 95
The Anti-Parkinsonian Drug Selegiline Delays the Nucleation Phase of α-Synuclein Aggregation Leading to the Formation of Nontoxic Species
Braga, C. A. C. A., Follmer, C., Palhano, F. L., Khattar, E., de Freitas, M. S., Romão, L. F., Giovanni, S. D., Lashuel, H. A., Silva, J. L., & Foguel, D. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.10.027 · Cited by 94
Minority enrollment in Parkinson's disease clinical trials
Schneider, M. G., Swearingen, C. J., Shulman, L. M., Ye, J., Baumgarten, M., & Tilley, B. C. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.06.005 · Cited by 93
Longitudinal evaluation of economic and physical impact of Parkinson's disease
Schenkman, M. L., Zhu, C. W., Cutson, T. M., & Whetten‐Goldstein, K. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00079-1 · Cited by 90
Older Swedish women's experiences of living with symptoms related to Parkinson's disease
Caap‐Ahlgren, M., Lannerheim, L., & PhD, O. D. M. (2002) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2002.02245.x · Cited by 89
Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics
Kay, D. M., Zabetian, C. P., Factor, S. A., Nutt, J. G., Samii, A., Griffith, A., Bird, T. D., Kramer, P., Higgins, D. S., & Payami, H. (2005) · Movement Disorders · doi:10.1002/mds.20751 · Cited by 89
Gradient boosting for Parkinson’s disease diagnosis from voice recordings
Karabayir, İ., Goldman, S. M., Pappu, S., & Akbilgiç, O. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01250-7 · Cited by 88
Self-citation
Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys
Johnston, L. C., Eberling, J. L., Pivirotto, P., Hadaczek, P., Federoff, H. J., Forsayeth, J., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.137 · Cited by 92
Proportionate mortality of crop and livestock farmers in the United States, 1984–1993
Lee, E., Burnett, C. A., Lalich, N. R., Cameron, L. L., & D, J. P. S. J. (2002) · American Journal of Industrial Medicine · doi:10.1002/ajim.10131 · Cited by 86
The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson’s disease
Al‐Hilaly, Y. K., Biasetti, L., Blakeman, B. J. F., Pollack, S. J., Zibaee, S., Abdul‐Sada, A. K., Thorpe, J. R., Xue, W., & Serpell, L. C. (2016) · Scientific Reports · doi:10.1038/srep39171 · Cited by 85
Parkinson's disease in women: A call for improved clinical studies and for comparative effectiveness research
Pavon, J. M., Whitson, H. E., & Okun, M. S. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.01.001 · Cited by 84
CD44 deficiency represses neuroinflammation and rescues dopaminergic neurons in a mouse model of Parkinson’s disease
Wang, Y., Li, L., Wu, Y., Zhang, S., Ju, Q., Yang, Y., Jin, Y., Shi, H., & Sun, C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106133 · Cited by 82
Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease
Caudle, W. M., Bammler, T. K., Lin, Y. S., Pan, S., & Zhang, J. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.54 · Cited by 90
Age‐related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: Relevance to selective neuronal vulnerability
Kanaan, N. M., Kordower, J. H., & Collier, T. J. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21333 · Cited by 82
Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells
Reynolds, A. D., Stone, D. K., Mosley, R. L., & Gendelman, H. E. (2009) · Journal of Proteome Research · doi:10.1021/pr9001614 · Cited by 83
Empirical Wavelet Transform Based Features for Classification of Parkinson’s Disease Severity
Oung, Q. W., Muthusamy, H., Basah, S. N., Lee, H. L., & Vijean, V. (2017) · Journal of Medical Systems · doi:10.1007/s10916-017-0877-2 · Cited by 81
Between destiny and disease: Genetics and molecular pathways of human central nervous system aging
Glorioso, C. A., & Sibille, E. L. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.11.006 · Cited by 83
Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model
Yadav, S. K., Prakash, J., Chouhan, S., Westfall, S., Verma, M., Singh, T. D., & Singh, S. P. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.12.001 · Cited by 80
Resting‐state functional connectivity of the striatum in early‐stage P arkinson's disease: Cognitive decline and motor symptomatology
Manza, P., Zhang, S., Li, C.-S. R., & Leung, H. (2015) · Human Brain Mapping · doi:10.1002/hbm.23056 · Cited by 79
Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region
Prete, E. D., Francesconi, A., Palermo, G., Mazzucchi, S., Frosini, D., Morganti, R., Coleschi, P., Raglione, L. M., Vanni, P., Ramat, S., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10002-6 · Cited by 79
“Increasing age is also considered an unequivocal risk factor for Parkinson’s Disease (PD) [8].”
Background
The Impact of Parkinson??s Disease on Health Status, Health Expenditures, and Productivity
Rubenstein, L. M., Chrischilles, E. A., & Voelker, M. D. (1997) · PharmacoEconomics · doi:10.2165/00019053-199712040-00006 · Cited by 78
Pluripotency of Stem Cells from Human Exfoliated Deciduous Teeth for Tissue Engineering
Rosa, V., Dubey, N., Islam, I., Min, K., & Nor, J. E. (2016) · Stem Cells International · doi:10.1155/2016/5957806 · Cited by 77
“[26] C.”
Parkinson's disease and the environment in early life
Martyn, C. N., & Osmond, C. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00148-u · Cited by 75
Is insulin-like growth factor-1 involved in Parkinson’s disease development?
Castilla‐Cortázar, I., Aguirre, G. A., Femat‐Roldán, G., Martín‐Estal, I., & Espinosa, L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02223-0 · Cited by 76
Clinical effects of chemical exposures on mitochondrial function
Zolkipli‐Cunningham, Z., & Falk, M. J. (2017) · Toxicology · doi:10.1016/j.tox.2017.07.009 · Cited by 74
“Aging is the main risk factor for PD (Tanner and Goldman 1996).”
Background
Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease
Rochester, L., Galna, B., Lord, S., Yarnall, A. J., Morris, R., Duncan, G. W., Khoo, T. K., Mollenhauer, B., & Burn, D. J. (2017) · Neurology · doi:10.1212/wnl.0000000000003840 · Cited by 73
Assistive devices for gait in Parkinson's disease
Constantinescu, R., Leonard, C., Deeley, C., & Kurlan, R. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.05.034 · Cited by 72
“Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting about 1% of individuals over the age of 65 years [1].”
Background
Risk factors for Parkinson's disease may differ in men and women: an exploratory study
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., & Rocca, W. A. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.05.013 · Cited by 73
Developing a large scale population screening tool for the assessment of Parkinson's disease using telephone-quality voice
Arora, S., Baghai-Ravary, L., & Tsanas, A. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5100272 · Cited by 71
Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease
McFarlane, D. (2007) · Ageing Research Reviews · doi:10.1016/j.arr.2007.02.001 · Cited by 70
Role of MCP-1 and CCR2 in alcohol neurotoxicity
Zhang, K., & Luo, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.030 · Cited by 70
“Parkinson’s disease (PD) is the second most common neurological disorder in the elderly after AD [68].”
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
Riederer, P. F., Nagatsu, T., Youdim, M. B. H., Wulf, M., Dijkstra, J. M., & Sian‐Hülsmann, J. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02630-9 · Cited by 71
Parkinson’s disease and dopamine transporter neuroimaging: a critical review
Shih, M. C., Hoexter, M. Q., de Andrade, L. A. F., & Bressan, R. A. (2006) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802006000300014 · Cited by 68
Emulation of Physician Tasks in Eye-Tracked Virtual Reality for Remote Diagnosis of Neurodegenerative Disease
Orlosky, J., Itoh, Y., Ranchet, M., Kiyokawa, K., Morgan, J. C., & Devos, H. (2017) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2017.2657018 · Cited by 68
“More recently, similar interfaces have been developed for studying eye trajectory and gait [34], retinal screening [13], and measuring the eye’s refractive error [21].”
Background
Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
Li, X., Cui, X., Chen, Y., Wu, T., Xu, H., Yin, H., & Wu, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00121 · Cited by 70
Prevalence of Parkinson?s disease and other types of Parkinsonism
Bergareche, A., la Puente, E. D., Sarasqueta, C., de Arce, A., Poza, J. J., Martí-Massó, J. F., & de Munaín, A. L. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0333-3 · Cited by 67
Pharmacological and Nonpharmacological Interventions in the Treatment of Parkinson's Disease
Cutson, T. M., Laub, K. C., & Schenkman, M. L. (1995) · Physical Therapy · doi:10.1093/ptj/75.5.363 · Cited by 67
Accuracy of medicare claims data in identifying Parkinsonism cases: Comparison with the medicare current beneficiary survey
Noyes, K., Liu, H., Holloway, R. G., & Dick, A. W. (2007) · Movement Disorders · doi:10.1002/mds.21299 · Cited by 66
THE DOPAMINERGIC NIGROSTRIATAL SYSTEMAND PARKINSON'S DISEASE
Hodaie, M., Neimat, J. S., & Lozano, A. M. (2007) · Neurosurgery · doi:10.1227/01.neu.0000249209.11967.cb · Cited by 66
Levodopa-Induced Neurotoxicity
Fahn, S. (1997) · CNS Drugs · doi:10.2165/00023210-199708050-00004 · Cited by 66
Trichloroethylene and Parkinson’s Disease: Risk Assessment
Liu, M., Shin, E., Dang, D., Jin, C., Lee, P. H., Jeong, J. H., Park, S., Kim, Y., Xing, B., Xin, T., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0830-x · Cited by 65
Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements
Reddy, A. P., Reddy, R. P., Roghani, A. K., Garcia, R. I., Khemka, S., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102410 · Cited by 72
A Guideline for Parkinson’s Disease Nurse Specialists, with Recommendations for Clinical Practice
Lennaerts, H. H., Groot, M. M., Rood, B., Gilissen, K., Tulp, H., van Wensen, E., Munneke, M., van Laar, T., & Bloem, B. R. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171195 · Cited by 65
Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease
Choi, H. S., Kim, H. J., Oh, J. H., Park, H.-G., Ra, J. C., Chang, K., & Suh, Y. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.022 · Cited by 64
Helicobacter Hypothesis for Idiopathic Parkinsonism: Before and Beyond
Dobbs, R. J., Dobbs, S. M., Weller, C., Charlett, A., Bjarnason, I., Curry, A., Ellis, D. S., Ibrahim, M. A. A., McCrossan, M. V., O’Donohue, J., et al. (2008) · Helicobacter · doi:10.1111/j.1523-5378.2008.00622.x · Cited by 62
Gender distribution of patients with Parkinson’s disease treated with subthalamic deep brain stimulation; a review of the 2000–2009 literature
Hariz, G., Nakajima, T., Limousin, P. D., Foltynie, T., Zrinzo, L. U., Jahanshahi, M., & Hamberg, K. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.12.002 · Cited by 65
“Clear evidence of any gender preponderance in prevalence of PD is lacking [6,8,11].”
Background
Role of Oxidative Damage in Protein Aggregation Associated with Parkinson's Disease and Related Disorders
Norris, E. H., & Giasson, B. I. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.672 · Cited by 61
Association between the oxidative polymorphism and early onset of Parkinson's disease*
Agúndez, J. A. G., Jiménez‐Jiménez, F. J., Luengo, A., Bernal, M. L., Molina, J. A., Ayuso, L. L., Vázquez, A., Parra, J., Duarte, J., Coria, F., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90154-x · Cited by 62
Developmental heptachlor exposure increases susceptibility of dopamine neurons to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)in a gender-specific manner
Richardson, J. R., Caudle, W. M., Wang, M. Z., Dean, E. D., Pennell, K. D., & Miller, G. W. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.05.007 · Cited by 61
Pharmacological effects of Astragalus polysaccharides in treating neurodegenerative diseases
Shi, Y., & Ma, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1449101 · Cited by 60
“It is estimated that the prevalence of PD in the general population is 0.3%, about 1% in people over 60 years old, and about 3% in people over 80 years old, with an incidence of 8 – 18 per 100,000 person-years (Tanner and Goldman, 1996; Nussbaum and Ellis, 2003).”
BackgroundInfluential
PET/CT in diagnosis of movement disorders
Berti, V., Pupi, A., & Mosconi, L. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06025.x · Cited by 60
Potential Role of Epigenetic Mechanism in Manganese Induced Neurotoxicity
Tarale, P., Chakrabarti, T., Sivanesan, S., Naoghare, P. K., Bafana, A., & Krishnamurthi, K. (2016) · BioMed Research International · doi:10.1155/2016/2548792 · Cited by 63
“Long term chronic exposure to certain metals like copper and manganese individually or in combination has been significantly found to be connected with increased risk of Parkinson’s disease [9, 127].”
Background
Parkinson's disease‐associated protein Parkin: an unusual player in cancer
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0314-z · Cited by 61
Gender distribution in surgery for Parkinson's disease
Hariz, G., & Hariz, M. I. (2000) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00009-2 · Cited by 60
Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
König, A., Miranda, H. V., & Outeiro, T. F. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171285 · Cited by 59
Drug discovery from natural products – Old problems and novel solutions for the treatment of neurodegenerative diseases
Maitra, U., Stephen, C. A., & Ciesla, L. M. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114553 · Cited by 57
Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: A systematic review
Chung, V. C., Liu, L., Bian, Z., Zhao, Z., Fong, W. L., Kum, W. F., Gao, J., & Li, M. (2006) · Movement Disorders · doi:10.1002/mds.21008 · Cited by 58
PHARMACODYNAMIC AND PHARMACOKINETIC CONSIDERATIONS IN GERIATRIC PSYCHOPHARMACOLOGY
Catterson, M. L., Preskorn, S., & Martin, R. L. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70401-9 · Cited by 58
Antioxidant strategies in protection against neurodegenerative disorders
Tan, D.-X., Manchester, L. C., Sainz, R. M., Mayo, J. C., Alvares, F. L., & Reiter, R. J. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1513 · Cited by 57
Gender ratio differences between Parkinson's disease patients and their affected relatives
Swerdlow, R. H., Parker, W. D., Currie, L. J., Bennett, J. P., Harrison, M., Trugman, J. M., & Wooten, G. F. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00029-8 · Cited by 58
A Family History of Parkinson’s Disease and Its Effect on Other PD Risk Factors
Rybicki, B. A., Johnson, C. C., Peterson, E. L., Kortsha, G. X., & Gorell, J. M. (1999) · Neuroepidemiology · doi:10.1159/000026222 · Cited by 56
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., Falzone, G. G., Giachino, C., Marchetti, B., & Iraci, N. (2021) · Aging and disease · doi:10.14336/ad.2021.0527 · Cited by 55
Different Prevalence Rates of Parkinson’s Disease in Urban and Rural Areas: A Population-Based Study in Taiwan
Chen, C. C., Chen, T., Hwang, Y. C., Wen, Y. R., Chiu, Y. H., Wu, C. Y., Chen, R. C., Tai, J. J., Chen, T. H. H., & Liou, H. (2009) · Neuroepidemiology · doi:10.1159/000254572 · Cited by 55
Tobacco Leaf, Smoke and Smoking, MAO Inhibitors, Parkinson's Disease and Neuroprotection; Are There Links?
Castagnoli, K. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00107-4 · Cited by 55
Informe de la Fundación del Cerebro sobre el impacto social de la enfermedad de Parkinson en España
García-Ramos, R., Valdés, E. L., Ballesteros, L., Jesús, S., & Mir, P. (2013) · Neurología · doi:10.1016/j.nrl.2013.04.008 · Cited by 54
Predication of Parkinson's disease using data mining methods: A comparative analysis of tree, statistical and support vector machine classifiers
Yadav, G., Kumar, Y., & Sahoo, G. (2012) · National Conference on Computing and Communication Systems (NCCCS) · doi:10.1109/ncccs.2012.6413034 · Cited by 54
Parkinsonism, FXTAS, and FMR1 premutations
Toft, M., Aasly, J. O., Bisceglio, G. D., Adler, C. H., Uitti, R. J., Krygowska‐Wajs, A., Lynch, T., Wszołek, Z. K., & Farrer, M. J. (2004) · Movement Disorders · doi:10.1002/mds.20297 · Cited by 54
Prevalence of Parkinson's disease in populations of African ancestry: a review.
McInerney-Leo, A. M., Gwinn, K. A., & Nussbaum, R. L. (2004) · PubMed Central · Cited by 53
Monoamine oxidase B inhibitors for early Parkinson's disease
Turnbull, K., Caslake, R., Macleod, A. D., Ives, N. J., Stowe, R. L., & Counsell, C. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004898.pub2 · Cited by 53
Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease
Lee, M. S., Lyoo, C. H., Ulmanen, I., Syvänen, A., & Rinne, J. O. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01749-3 · Cited by 53
Rotenone and paraquat perturb dopamine metabolism: A computational analysis of pesticide toxicity
Qi, Z., Miller, G. W., & Voit, E. O. (2013) · Toxicology · doi:10.1016/j.tox.2013.11.003 · Cited by 53
GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease
Guan, J., Yang, B., Fan, Y., & Zhang, J. (2017) · Neuroimmunomodulation · doi:10.1159/000478908 · Cited by 53

Authors: Tanner, C. M., & Goldman, S. M.
Affiliations: Parkinson's Institute and Clinical Center (US)
ORCID: Tanner, Caroline M.
Goldman, Samuel M.
Venue: Neurologic Clinics
Publisher: Elsevier BV
Published: 1996-05
Volume: 14
Issue: 2
Pages: 317-335
ISSN: 0733-8619 (ISSN-L)
DOI: 10.1016/s0733-8619(05)70259-0
PMC: PMC7173037
OpenAlex: W2084553926
Semantic Scholar: 722f96a983f226977773068a6a70c00979c0cbd5
Cited by: 640
References: 240
Citations by year: 2026: 9 · 2025: 10 · 2024: 17 · 2023: 29 · 2022: 23 · 2021: 26 · 2020: 14 · 2019: 24 · 2018: 35 · 2017: 36 · 2016: 28 · 2015: 26 · 2014: 32 · 2013: 28 · 2012: 19
FWCI: 11.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neurologic Clinics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA094089)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, etiology, complex diseases, genetic risk factors, environmental risk factors, incidence, prevalence, levodopa, early markers, disease susceptibility, disease progression
MeSH terms: Aged, Consanguinity, Diet, Environmental Exposure, Female, Humans, Male, Middle Aged, Parkinson Disease, Risk Factors, Smoking, Global Health, Hazardous Substances, Incidence, Prevalence, Age Distribution, Sex Distribution, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks